Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Argent BioPharma Ltd - Subiaco, Western Australia-based drug discovery company - Pretax loss narrows to A$17.5 million in the financial year ended June 30, from A$21.1 million a year prior. Revenue from contracts with customers dives to A$891,083 from A$3.4 million. Cost of sales decrease to A$687,386 from A$1.9 million. Notably, Argent Biopharma reports a gain from a fair value movement on financial instruments of A$1.3 million, compared to a cost of A$4.5 million in financial 2023.
Current stock price: 16.15 pence each, closed 13% lower on Friday in London
12-month change: down 23%
Copyright 2024 Alliance News Ltd. All Rights Reserved.